Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R J Motzer

Showing results (111-120 of 155) with videos related to

Pageof 16
Sort By:
Cancer|June 1, 1990
Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumorsR J Motzer, K Cooper, N L Geller, et al.
Annals of Internal Medicine|April 1, 1988
Advanced seminoma: the role of chemotherapy and adjunctive surgeryR J Motzer, G J Bosl, N L Geller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 1999
Up-regulation of retinoic acid receptor beta expression in renal cancers in vivo correlates with response to 13-cis-retinoic acid and interferon-alpha-2aW J Berg, D M Nanus, A Leung, et al.
Cancer|September 1, 1995
Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinomaT M Law, R J Motzer, M Mazumdar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1993
Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancerA D Seidman, H I Scher, J L Gabrilove, et al.
Cancer Research|October 15, 1992
Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expressionR J Motzer, D M Nanus, P O'Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2000
Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patientsR J Motzer, M Mazumdar, J Sheinfeld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2000
Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinomaR J Motzer, B A Murphy, J Bacik, et al.
ESMO Open|May 24, 2025
Health-related quality-of-life profile and clinical outcomes in first-line advanced renal cell carcinoma: a modeling analysis based on the CheckMate 9ER studyD Cella, M Derosa, L Floden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1993
Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional studyD F Bajorin, M F Sarosdy, D G Pfister, et al.
Pageof 16

Showing results (111-120 of 155) with videos related to

Sort By:
Pageof 16
Cancer|June 1, 1990
Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumorsR J Motzer, K Cooper, N L Geller, et al.
Annals of Internal Medicine|April 1, 1988
Advanced seminoma: the role of chemotherapy and adjunctive surgeryR J Motzer, G J Bosl, N L Geller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 1999
Up-regulation of retinoic acid receptor beta expression in renal cancers in vivo correlates with response to 13-cis-retinoic acid and interferon-alpha-2aW J Berg, D M Nanus, A Leung, et al.
Cancer|September 1, 1995
Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinomaT M Law, R J Motzer, M Mazumdar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1993
Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancerA D Seidman, H I Scher, J L Gabrilove, et al.
Cancer Research|October 15, 1992
Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expressionR J Motzer, D M Nanus, P O'Moore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2000
Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patientsR J Motzer, M Mazumdar, J Sheinfeld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2000
Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinomaR J Motzer, B A Murphy, J Bacik, et al.
ESMO Open|May 24, 2025
Health-related quality-of-life profile and clinical outcomes in first-line advanced renal cell carcinoma: a modeling analysis based on the CheckMate 9ER studyD Cella, M Derosa, L Floden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1993
Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional studyD F Bajorin, M F Sarosdy, D G Pfister, et al.
Pageof 16